Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Actinium Pharmaceuticals Inc
ATNM
Healthcare
Biotechnology
Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A...
is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The Company focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The Company holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NYSEAM:ATNM)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
Next
(83)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Feb 26, 2024 11:15am
Actinium Announces Iomab-B Markedly Increases Long Term Surv
NEWS: $ATNM Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem
...more
(83)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Feb 16, 2024 2:00pm
How to Take Advantage of moves in (ATNM)
BREAKING NEWS: $ATNM How to Take Advantage of moves in (ATNM)2024-02-16 07:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to
...more
C.RVV Announces Type C Meeting Request Granted by FDA for Clinical Study
posted Apr 24, 2024 9:00am by
Revive Therapeutics Ltd.
-
|
Currently, the Company is exploring the use of Bucillamine as a potential treatment for long COVID. The Company is advancing the clinical development of Bucillamine by leveraging the published research and data from its previous Phase 3 clinical trial (the “Study”) and is finalizing the regulatory and clinical package that includes a proposed clinical study for long COVID to present to the FDA ...read more
(0)
•••
EllaMae
X
View Profile
View Bullboard History
Post by
EllaMae
on Apr 13, 2023 3:43am
Kevin Harrington Discusses FSD Pharma
I believe this new product will aid society in reducing the
...more
(27)
•••
BryceCanada
X
View Profile
View Bullboard History
Post by
BryceCanada
on Nov 02, 2022 5:07pm
And good supporting article!
https://trendingmarketnews.com/biotechs-next-generational-breakout/
(27)
•••
BryceCanada
X
View Profile
View Bullboard History
Post by
BryceCanada
on Nov 02, 2022 5:05pm
Excellent YT analysis on ATNM!
https://youtu.be/EBO7c8N5bSI
(5)
•••
wabomebuypo16
X
View Profile
View Bullboard History
Post by
wabomebuypo16
on Nov 02, 2022 9:32am
TIME TO TURN NORTH
BULLALERTS is a must for any trader. Their watchlist which covers pre-market movers is one of the best researched in the industry. I dont start trading without reading their daily email each morning!
(0)
•••
EllaMae
X
View Profile
View Bullboard History
Post by
EllaMae
on Jul 15, 2022 9:20pm
FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent
(0)
•••
EllaMae
X
View Profile
View Bullboard History
Post by
EllaMae
on Jun 03, 2022 5:04am
FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance
FSD Pharma ready to proceed with Phase 2 clinical trial of
...more
(0)
•••
EllaMae
X
View Profile
View Bullboard History
Post by
EllaMae
on Jun 02, 2022 12:16am
FSD Pharma Files Investigational New Drug Application “IND”
(0)
•••
EllaMae
X
View Profile
View Bullboard History
Post by
EllaMae
on May 11, 2022 1:25am
FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets
(0)
•••
EllaMae
X
View Profile
View Bullboard History
Post by
EllaMae
on May 03, 2022 10:28pm
Lucid-MS for Multiple Sclerosis Treatment
(0)
•••
EllaMae
X
View Profile
View Bullboard History
Post by
EllaMae
on Apr 26, 2022 1:37am
"Julia Levy Award" Recipient David Allan and Dr. John McGraw
(0)
•••
EllaMae
X
View Profile
View Bullboard History
Post by
EllaMae
on Apr 19, 2022 10:54pm
FSD Pharma Inc: Lucid MS Video
FSD Pharma is delighted to announce pre-clinical findings
...more
(0)
•••
EllaMae
X
View Profile
View Bullboard History
Post by
EllaMae
on Apr 09, 2022 2:45am
FSD: Cancellation of Certain Shares Issued to Former CEO
FSD Pharma Announces Cancellation of Certain Shares Issued to Former Chief Executive Officer Dr. Raza Bokhari TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A)
...more
(0)
•••
EllaMae
X
View Profile
View Bullboard History
Post by
EllaMae
on Apr 07, 2022 12:16pm
FSD Pharma Issues Corporate Updates
FSD Pharma Issues Corporate Updates TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to
...more
Prev
1
2
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover a Green Resources Stock Scoring Record Quarterly Growth
Stage Set for Creation of a Leading Intermediate Gold Producer
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study